NVO - Weightloss Drugs Ozempic And Wegovy's Success Sets Novo Nordisk's Owner To Utilize Dividend Windfall For Strategic Investments | Benzinga
In a recent interview, Kasim Kutay, Chief Executive Officer of Novo Holdings, announced the company’s ambitious plans for further acquisitions and investments, particularly in Asia.
As the main owner of Novo Nordisk A/S (NYSE:NVO), Novo Holdings, holding 77% of the votes, is gearing up for an active role in dealmaking.
Kutay emphasized the need to scale up and strategically utilize the dividends from Novo Nordisk’s highly successful medicines for obesity and diabetes.
A comprehensive U.S. study revealed that the use of Novo Nordisk A/S’s NVO drugs Ozempic and Wegovy, widely prescribed for type 2 diabetes and obesity, respectively, is not associated with ...